相关实验视频
Updated: Jun 13, 2025

Electrocardiogram Recordings in Anesthetized Mice using Lead II
Published on: June 20, 2020
卡格利林提德与临床相关的QTc延长无关:对健康参与者的彻底QT研究
Maria B N Gabe1, Rainard Fuhr2, Angela Sinn2
1Novo Nordisk A/S, Søborg, Denmark.
卡格利林提德是一种新的肥胖症和2型糖尿病药物,在一项彻底的QT研究中没有显示出临床相关的心脏再极化延长. 这表明,随着卡格利林提德治疗,心室动脉节律失常的风险没有增加.
科学领域:
- 药理学 药理学是指药理学的学科.
- 心脏病学 心脏病学
- 代谢疾病 代谢疾病
背景情况:
- 卡格利林提德正在开发用于治疗肥胖和2型糖尿病.
- 评估心脏安全对于新药开发至关重要.
研究的目的:
- 为了评估卡格里林提德对心脏再极化的影响.
- 为了确定卡格利林提德是否与安慰剂相比延长了QT间隔.
主要方法:
- 进行了一项双盲,安慰剂控制的全面QT研究.
- 参与者接受了加格利林提德或安慰剂的升级剂量.
- 主要终点是Fridericia心率校正的QT间隔 (QTcF) 与基线的变化.
主要成果:
- 没有观察到与卡格利林提德的临床相关的QTcF延长.
- 对于QTcF变化的90%置信区间的上限低于10 ms.
- 莫西弗洛克萨辛证实了QT测试的灵敏度.
结论:
- 卡格利林提德不会导致临床相关的QTcF延长.
- 与卡格利林提德相关的腹腔动脉节律失常的风险没有增加.
更多相关视频
14:03High-Throughput Cardiotoxicity Screening Using Mature Human Induced Pluripotent Stem Cell-Derived Cardiomyocyte Monolayers
Published on: March 24, 2023
08:28Methods for ECG Evaluation of Indicators of Cardiac Risk, and Susceptibility to Aconitine-induced Arrhythmias in Rats Following Status Epilepticus
Published on: April 5, 2011
相关概念视频
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Imaging Studies for Cardiovascular System I:Echocardiography
Indications: Echocardiography is utilized to diagnose heart failure, valve disorders, and myocardial infarction. It also assesses cardiac structures' size, shape, and motion,...